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Abstract
Full thickness articular cartilage defects have limited regenerative potential and are a significant source of pain and
loss of knee function. Numerous treatment options exist, each with their own advantages and drawbacks. The goal
of this review is to provide an overview of the problem of cartilage injury, a brief description of current treatment
options and outcomes, and a discussion of the current principles and technique of Matrix-induced Autologous
Chondrocyte Implantation (MACI). While early results of MACI have been promising, there is currently insufficient
comparative and long-term outcome data to demonstrate superiority of this technique over other methods for
cartilage repair.
Introduction
Isolated chondral or osteochondral lesions of the knee
are regularly found in a population undergoing knee
arthroscopy [1,2]. Origins include traumatic injuries,
abnormal joint loading, and osteochondritis dissecans
among others. Cartilage lesions are often found in asso-
ciation with anterior cruciate ligament injuries, disloca-
tions of the patella, limb malalignment, patellar
maltracking and following significant meniscectomy
[2-5]. Determining the ideal treatment of these lesions is
problematic because it is often difficult to determine
whether the patient’s symptoms are caused by the carti-
lage lesion or by an associated pathology. It has been
shown that even in isolation, these lesions may lead to
significant pain and disability [6].
Damaged articular cartilage has limited or no healing
capacity due its relative metabolic inactivity and lack of
blood supply that permits only a limited response to
injury [7,8]. These lesions may progress to generalized
osteoarthritis over time [9]. Repairing isolated full-thick-
ness cartilaginous defects has been therefore proposed
to treat symptoms and prevent the development of
osteoarthritis. Successful early treatment of these lesions
would be of great benefit to patients as well as the
health care system, as long-term morbidity and conse-
quent high use of health service resources could be
avoided [10]. Imaging studies facilitate the diagnosis of
isolated cartilage lesions. MRI has been established as
the diagnostic gold standard and should be considered
when a chondral injury is suspected [11,12].
Many treatment options have been developed during
the last decades to repair damaged articular cartilage
[13]. The techniques can be grouped as bone marrow
stimulation techniques such as drilling [14], abrasion
[15], microfracture [16] and autologous matrix induced
chondrogenesis (AMIC) [17]; direct chondral replace-
ment techniques such as mosaicplasty [18], fresh osteo-
chondral allograft transplantation [19], and periosteal
transplantation [20]; and culture-based techniques such
as Autologous Chondrocyte Implantation (ACI) [21] and
Matrix-induced Autologous Chondrocyte Implantation
(MACI) [22]. Each of these procedures can be per-
formed in association with new techniques, materials, or
growth factors, leading to the description of a huge
number of treatment options that have been used in
experimental and clinical settings [23].
This review will provide an overview on the historical
development of cartilage repair. The main focus will be
on the MACI technique and its variants and the clinical
evidence for its use compared to other cartilage repair
procedures.
Historical development of cartilage repair
As early as 1743 William Hunter stated that “ulcerated
cartilage is a troublesome thing, once destroyed it is not
repaired” [24]. In 1853 James Paget reported that there
are “no instances in which a lost portion of cartilage has
been restored, or a wounded portion repaired with new
and well formed cartilage” [25].
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operative treatment of diseased portions of articular sur-
faces. His concept of complete debridement of the knee
joint for osteoarthritis was novel and original. He deb-
rided the joint, including removal of osteophytes and a
kind of abrasion was done [26]. Pridie took up the princi-
ple of Magnuson and described his own technique in
1951 [14]. On previously eburnated joint surfaces he per-
formed drill holes via an open approach, perforating the
subchondral lamina. He observed the growth of repair
tissue and pain relief in his patients. This technique has
shown to provide significant symptomatic improvement
in 75% of patients at a mean of eight years following sur-
gery [27]. Later, Johnson popularized arthroscopic abra-
sion arthroplasty, which was also based on Magnuson’s
experiences [15]. The subchondral lamina was removed
with an arthroscopic burr, releasing mesenchymal stem
cells into the lesion and promoting the formation of
repair tissue. Abrasion was often combined with lavage,
debridement and partial meniscectomy. The technique
was noted to relieve pain for up to 5 years, with better
results noted in younger patients [28].
In the early 1990s, Steadman described the Microfrac-
ture technique [16,29]. He performed multiple perfora-
tions of the subchondral lamina with an arthroscopic
awl. Possible advantages of this technique include avoid-
ance of heat necrosis, which might be associated to the
use of a drill burr, and preservation of enough subchon-
dral bone to avoid any risk of collapse. Additionally, the
development of angled awls allowed access to regions
that were difficult to reach arthroscopically with a drill
or burr. Encouraging results have noted at medium-
term follow-up, especially in younger patients; however,
around 20% of patients are generally not satisfied after
five years [30-32].
A final variant of bone marrow stimulation is the
autologous matrix induced chondrogenesis (AMIC)
technique published in 2005 by Behrens [17]. Following
microfracture, a collagen scaffold is placed over the
defect, holding the blood clot and mesenchymal stem
cells released from the marrow in place over the defect,
theoretically aiding the cartilage repair process [17].
Their group has reported good early results at a mean
of three years post-operative [33].
R e g a r d l e s so ft h es p e c i f i ct e c h n i q u e ,b o n em a r r o w
stimulating procedures generally induce the formation
of fibrocartilage as repair tissue [30,34]. This tissue has
limited mechanical resistance compared with hyaline
cartilage, potentially leading to earlier degradation and
subsequent failure [35]. For this reason, alternative pro-
cedures have been developed in an attempt to create
hyaline repair tissue.
Replacement of the injured cartilage is one such
approach to restore the joint surface. Osteochondral
Autograft Transplantation (OAT) and mosaicplasty are
techniques in which the injured cartilage is replaced with
osteochondral plugs taken from non-weightbearing por-
tion of the joint. Hangody initially described this techni-
que in the 1990s and has demonstrated successful
transplantation of autologous hyaline cartilage [18,29,36].
A single plug may be sufficient for small lesions, while
larger lesions frequently require several grafts. Depending
on lesion size and location, an open or arthroscopic
approach may be undertaken. Alternatively, fresh osteo-
chondral allografts can have been proposed for full-thick-
ness osteochondral defects, particularly for defects greater
than 3 cm in diameter or 1 cm in depth of the femoral
condyles [19]. The success of mosaicplasty is limited in
these large lesions due to donor site morbidity and heal-
ing seams at the recipient site. Results of mosaicplasty
are often satisfactory in the medium term with slight
deterioration over time [37,38].
Based on the work of Bentley and Greer, there has
been increasing interest in the ability of transplanted
chondrocytes to reform damaged articular cartilage [5].
Autologous chondrocyte implantation (ACI) was the
first example of tissue engineering in cartilage repair.
ACI was first utilized in humans in 1987 and first
reported by Brittberg in 1994 [21]. In this technique,
cultured chondrocytes are injected under a periosteal
cover, which is sutured onto the defect. In order to con-
tain the cultured chondrocytes in the defect, a water-
tight suture of the periosteum to the surrounding
cartilage is required. A preliminary surgery is necessary
to harvest autologous cartilage, followed by several
weeks of cell culture. The technique changed over time
to the second generation ACI, in which the periosteal
membrane was replaced by a collagen scaffold [39]. ACI
has been reported to yield good outcomes in a large
percentage of patients as long as 10 to 20 years after
implantation [40].
A later development was to culture the autologous
chondrocytes on a three-dimensional artificial scaffold.
This third generation chondrocyte transplantation tech-
nique, commonly referred to as the matrix-induced
autologous chondrocyte implantation (MACI) technique,
is detailed in the next section [22,41].
During the last two decades tremendous effort has
been undertaken to shorten cell culture, engender other
cells with chondrocyte-like characteristics, and to pro-
duce tissue easier for the surgeon to implant [31,42-44].
However few of these experimental developments have
reached clinical application.
MACI procedure
Principle
The technical difficulty and need for a relatively large
arthrotomy associated with the traditional ACI procedure
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sue have spurred the desire to develop an easier, more
effective method of implanting cultured chondrocytes
into the knee joint [41,45]. The principle is to culture
autologous cells onto a three dimensional biocompatible
scaffold, which is then implanted into the defect (Figure
1). As with the ACI technique, an initial arthroscopic
harvest is necessary to obtain chondrocytes for culture. A
full-thickness cartilage specimen is generally taken from a
non-weightbearing region of the knee joint such as the
area around the intercondylar notch or the lateral border
of the trochlea. This initial surgery is also an opportunity
to evaluate the lesion and to confirm the indication.
Graft preparation
The cartilage biopsy is enzymatically digested to release
the chondrocytes entrapped in the collagen matrix.
Expansion of chondrocytes is generally performed in
monolayer culture to obtain fifteen to twenty million
cells over about four weeks. A few days before implanta-
tion, the expanded chondrocytes are seeded onto a
biodegradable scaffold [41]. A common problem in
monolayer expansion of chondrocytes is the dedifferen-
tiation of cells. Seeding of the cells onto a three dimen-
sional collagen I/III scaffold can lead to at least partial
redifferentiation. It has been shown that cells grown on
the scaffold can synthesize typical chondrocyte matrix
components including glycosaminoglycans, chondroitin
sulfate and type II collagen. The S-100 protein, which is
a cytoplasmic marker of chondrocytes, has also been
detected [22,46,47].
Several different scaffolds are currently used in clinical
settings. The matrix-induced ACI (MACI) method
(Genzyme Biosurgery, Cambridge, Massachusetts, USA)
relies on a purified and cell-free porcine collagen scaf-
fold [41]. Hyalograft-C (Fidia Advanced Biopolymers,
Abano Terme, Italy) utilizes a scaffold based on hyaluro-
nic acid [48]. Novocart 3D (TETEC Tissue Engineering
Technologies AG, Reutlingen, Germany) uses a col-
lagen-chondroitin-sulfate based membrane. [49] Bio-
Seed-C (Biotissue Technologies, Freiburg, Germany)
relies on a fibrin and polymer-based scaffold of polygly-
colic/polylactic acid and polydioxanone [50]. Cartipatch
(Tissue Bank of France, Lyon, France) utilizes an agar-
ose-alginate hydrogel scaffold [51]. Only the MACI
technique is currently available in the United States. It
has the largest clinical experience and the majority of
published reports, including two randomized clinical
trials, refer to this technique. For these reasons, our
review will focus on the MACI technique.
Surgical technique
Implantation of the scaffold can be performed in an open
or arthroscopic manner depending on the size and loca-
tion of the lesion. The cartilage defect is first debrided
down to the calcified cartilage layer without penetration
of the subchondral lamina. The border of the lesion is
then prepared to achieve stable and vertical edges. The
cultured cartilage implant must then be trimmed to
exactly match the defect size and not protrude beyond
the margins. The implant is then fixed into the defect
with a minimal amount of fibrin glue. The cell-seeded
side is placed facing the subchondral bone. Pressure is
applied for several minutes to ensure fixation. In uncon-
tained and large defects the use of biodegradable bone
anchors or limited suture fixation may be necessary to
avoid graft delamination [41]. Surgical time is typically
shorter than traditional ACI as implantation and fixation
Figure 1 The MACI procedure. (1) Initial arthroscopy with evaluation of the injured cartilage and harvest of a full-thickness cartilage biopsy; (2)
the biopsy is sent in a sterile and cooled container to the cell culture laboratory; (3) the cartilage is enzymatically digested; (4) expansion of the
chondrocytes in monolayer culture for about four weeks; (5) the cells are seeded onto the scaffold a few days before implantation; (6) the
engineered implant is sent back to the surgeon in a sterile container; (7) definitive surgery with debridement of the injured cartilage followed by
implantation of the MACI-implant, which is trimmed to fit the defect size and glued with a thin layer of fibrin glue.
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currently with other interventions such as ligamentous
reconstruction, bone grafting or high tibial osteotomy
[52].
Rehabilitation
The goal of rehabilitation is to safely restore knee func-
tion including range of motion, muscle strength, and
coordination while protecting the implanted graft during
its maturation. After a short initial immobilization per-
iod, continuous passive motion (CPM) is recommended
as it has been shown to stimulate synthesis of glycosa-
minoglycans, chondroitin sulfate and type II collagen
[53]. Typically, eight to twelve weeks of limited weight
bearing and progressive range of motion are advocated,
followed by progressive advancement of activity level. A
randomized controlled trial comparing standard (eleven
weeks) versus accelerated (eight weeks) rehabilitation
found no negative influence of accelerated rehabilitation
at three months [54]; however, mid- and long-term
results are not available. Full return to sports activities
is generally not permitted until 18 months after surgery.
Results and State of the Evidence
MACI Procedure
MACI has been reported to be a successful method to
treat symptomatic isolated cartilage defects. Many case
series (level 4 evidence) are available reporting improve-
ment of pain and function after this procedure in short-
and medium-term follow-up [22,39,48,49,55-60]. Rele-
vant clinical studies are summarized in table 1. MRI
evaluation generally demonstrates filling of the cartilage
defect; however, some hypertrophy, incomplete filling,
and limited integration with surrounding normal carti-
lage has been noted at up to 60 months postoperatively
[39]. No data is currently available demonstrating that
this procedure prevents or delays the development of
osteoarthritis. Unfortunately, the vast majority of clinical
evidence regarding MACI is based on small case series
using a variety of techniques on heterogenous patient
populations, the results of which are evaluated with a
plethora of incomparable outcome measures. These fac-
tors impair the ability to compare results between stu-
dies, which are often contradictory [61].
Postoperative complications and adverse events asso-
ciated with the MACI procedure have been reported in
clinical studies, including tissue hypertrophy, infections,
the need for subsequent surgical procedures, and treat-
ment failure [22,39,45,62,63]. Reported incidence rates
of postoperative complications are generally low (0-
6.3%) [39,45,63]. One of the more common problems is
hypertrophy of the repair site, which can be arthroscopi-
cally debrided [45].
Comparative Studies
In spite of significant research, none of the techniques
described above consistently demonstrate superior clinical
outcomes compared to the others [61,64], with some
authors noting improved results with ACI [65] or mosaic-
plasty [66] compared with marrow stimulation techniques
and other noting no difference [30,34,59]. One rando-
mized controlled trial comparing mosaicplasty to ACI
favored mosaicplasty [67] another favored ACI [68].
Four prospective comparative studies are currently
available that compare MACI to another cartilage repair
procedure. Basad et al [69], Kon et al [70], and Visna
Table 1 Clinical Results of MACI
Author Patients Follow-up
(months)
Study design Major Findings
Basad [69] 60 24 Level I
RCT versus Microfracture
Significantly larger improvements in Lysholm, Tegner and ICRS scores were noted in
the MACI group
Visna[71] 50 12 Level I
RCT versus microfracture
Significantly larger improvements in Lysholm, Tegner and IKDC scores were noted
in the MACI group
Kon[70] 80 60 Level II
Prospective cohort versus
microfracture
Significantly larger improvement in IKDC score was noted in the MACI group.
Results deteriorated from 2 to 5 years in microfracture but not MACI group
Bartlett
[45]
47 12 Level I
RCT versus ACI
Significant improvements in Cincinnati score and VAS were noted in both group -
no significant differences between the two groups
Wondrasch
[60]
31 24 Level 1
RCT Standard versus
accelerated rehabilitation
Significant improvements in IKDC, KOOS, Lysholm and Tegner scores were noted in
both group - no significant differences between the two groups
Behrens
[22]
34 34 Level IV
Case series
Significant improvements in Meyer, Lysholm and ICRS scores
Ebert[64] 35 120 Level IV
Case series
Significant improvements in KOOS, SF-36 and MRI composite scores
D’Anchise
[48]
35 24 Level IV
Case series
Significant improvements in VAS, IKDC, Lysholm and Tegner scores
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stimulation techniques. Basad et al and Visna et al
found the MACI procedure to be superior to marrow
stimulation techniques at short-term follow-up (1 to
2 years) [70,71]. Kon et al noted some deterioration
of microfracture results between 2 and 5 years post-
operative, while MACI results were unchanged [69],
Bartlett et al compared MACI with traditional ACI and
noted no significant differences between the two groups
[45]. Importantly, there are currently no studies compar-
ing patients treated with MACI to an untreated control
group.
Conclusions
The MACI technique is a safe procedure for the treatment
of symptomatic articular cartilage lesions. It is a two-step
procedure relying on expensive cell culture techniques.
Technically, it facilitates surgery and reduces operative
time and the need for open surgery compared to tradi-
tional ACI. Symptomatic improvement has been shown at
short- and medium-term follow-up. Available comparative
studies suggest that MACI may be superior to marrow sti-
mulation techniques, but long-term outcome data and
comparisons against conservative management are lacking.
No data are currently available demonstrating its capacity
to prevent or delay the onset of osteoarthritis. The role of
MACI in cartilage repair surgery remains a subject of
intense investigation and has yet to be fully defined.
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